Australia - English - Department of Health (Therapeutic Goods Administration)

stallergenes australia pty ltd - cynodon dactylon, quantity: 0.14 ml/ml (equivalent: cynodon dactylon, qty 7 mg/ml); sorghum halepense, quantity: 0.14 mg/ml (equivalent: sorghum halepense, qty 7 mg/ml); poa pratensis, quantity: 0.14 mg/ml (equivalent: poa pratensis, qty 7 mg/ml); dactylis glomerata, quantity: 0.14 ml/ml (equivalent: dactylis glomerata, qty 7 mg/ml); poa nemoralis, quantity: 0.14 ml/ml (equivalent: poa nemoralis, qty 7 mg/ml); anthoxanthum odoratum, quantity: 0.14 mg/ml (equivalent: anthoxanthum odoratum, qty 7 mg/ml); phle - extract, liquid - excipient ingredients: glycerol; sodium chloride; sodium bicarbonate; water for injections - indicated use of allergenic extracts is for the diagnosis and treatment (hypo-sensitization therapy) of patients who experience allergic symptoms.

Malta - English - Medicines Authority

stallergenes s.a. 6 rue alexis de tocqueville, 92160 antony, france - grass pollen, allergen extract - sublingual tablet - grass pollen allergen extract 300 ir - allergens

United States - English - NLM (National Library of Medicine)

stallergenes - phleum pratense pollen (unii: 65m88rw2eg) (phleum pratense top - unii:s7pw24bx20, phleum pratense pollen - unii:65m88rw2eg), anthoxanthum odoratum pollen (unii: 2kik19r45y) (anthoxanthum odoratum pollen - unii:2kik19r45y), dactylis glomerata pollen (unii: 83n78ida7p) (dactylis glomerata pollen - unii:83n78ida7p), poa pratensis pollen (unii: scb8j7ls3t) (poa pratensis pollen - unii:scb8j7ls3t), lolium perenne pollen (unii: 4t81lb52r0) (lolium perenne pollen - unii:4t81lb52r0) - anthoxanthum odoratum pollen 100 [ir] - oralair is an allergen extract indicated as immunotherapy for the treatment of grass pollen-induced allergic rhinitis with or without conjunctivitis confirmed by positive skin test or in vitro testing for pollen-specific ige antibodies for any of the five grass species contained in this product. oralair is approved for use in persons 5 through 65 years of age. oralair is not indicated for the immediate relief of allergy symptoms. oralair is contraindicated in patients with: - severe, unstable or uncontrolled asthma - history of any severe systemic allergic reaction - history of any severe local reaction to sublingual allergen immunotherapy - a history of eosinophilic esophagitis - hypersensitivity to any of the inactive ingredients (mannitol, microcrystalline cellulose, croscarmellose sodium, colloidal anhydrous silica, magnesium stearate and lactose monohydrate) contained in this product [ see description (11) ] risk summary all pregnancies have a risk of birth defect, loss, or other adverse outcomes.

Australia - English - Department of Health (Therapeutic Goods Administration)

stallergenes australia pty ltd - lolium perenne, quantity: 2 ir/ml; phleum pratense, quantity: 2 ir/ml; poa pratensis, quantity: 2 ir/ml; anthoxanthum odoratum, quantity: 2 ir/ml; dactylis glomerata, quantity: 2 ir/ml - injection, suspension - excipient ingredients: phenol; aluminium hydroxide hydrate; water for injections; sodium chloride; mannitol - treatment of patients with type 1 allergy (gell and coombs classification), particularly presenting as seasonal or perennial rhinitis, conjunctivitis, rhinoconjunctivitis, with or without associated asthma.

Australia - English - Department of Health (Therapeutic Goods Administration)

stallergenes australia pty ltd - sorghum halepense, quantity: 1 ml/ml (equivalent: sorghum halepense, qty 50 mg/ml) - extract, liquid - excipient ingredients: glycerol; sodium chloride; sodium bicarbonate; water for injections - indicated use of allergenic extracts is for the diagnosis and treatment (hypo-sensitization therapy) of patients who experience allergic symptoms.

Australia - English - Department of Health (Therapeutic Goods Administration)

stallergenes australia pty ltd - poa nemoralis, quantity: 1 ml/ml (equivalent: poa nemoralis, qty 50 mg/ml) - extract, liquid - excipient ingredients: glycerol; sodium chloride; sodium bicarbonate; water for injections - indicated use of allergenic extracts is for the diagnosis and treatment (hypo-sensitization therapy) of patients who experience allergic symptoms.

Australia - English - Department of Health (Therapeutic Goods Administration)

stallergenes australia pty ltd - dactylis glomerata, quantity: 1 ml/ml (equivalent: dactylis glomerata, qty 50 mg/ml) - extract, liquid - excipient ingredients: glycerol; sodium chloride; sodium bicarbonate; water for injections - indicated use of allergenic extracts is for the diagnosis and treatment (hypo-sensitization therapy) of patients who experience allergic symptoms.

Israel - English - Ministry of Health

trupharm marketing 1985 ltd. - food extract - solution for injection - food extract - allergen extracts - skin testing and immunotherapy.

Ireland - English - HPRA (Health Products Regulatory Authority)

stallergenes - grass pollen allergen extract - sublingual tablet - 100/300 index of reactivity - allergen extracts; grass pollen

Australia - English - Department of Health (Therapeutic Goods Administration)

stallergenes australia pty ltd - poa pratensis, quantity: 20 %; anthoxanthum odoratum, quantity: 20 %; phleum pratense, quantity: 20 %; dactylis glomerata, quantity: 20 %; lolium perenne, quantity: 20 % - tablet - excipient ingredients: microcrystalline cellulose; croscarmellose sodium; magnesium stearate; colloidal anhydrous silica; lactose monohydrate - treatment of grass pollen allergic rhinitis with or without conjunctivitis in adults, adolescents and children (above the age of 5) with clinically relevant symptoms, confirmed by a positive cutaneous test and/or a positive titre of the specific ige to the grass pollen.